首页>
外国专利>
Pharmaceutical dosage form has the properties of an immediate release and / or controlled release formulations that CONTAIN GABAB receptor agonist
Pharmaceutical dosage form has the properties of an immediate release and / or controlled release formulations that CONTAIN GABAB receptor agonist
展开▼
机译:药物剂型具有包含GABAB受体激动剂的立即释放和/或控释制剂的特性
展开▼
页面导航
摘要
著录项
相似文献
摘要
1.u0444u0430u0440u043cu0430u0446u0435u0432u0442u0438u0447u0435u0441u043au0430u00a0 u043bu0435u043au0430u0440u0441u0442u0432u0435u043du043du0430u00a0 form with controlled release u0432u043au043bu044eu0447u0430u044eu0449u0430u00a0 component in which the component with controlled release contains u0430u0433u043eu043du0438 art u0440u0435u0446u0435u043fu0442u043eu0440u0430 u0433u0430u043cu043au0432 and u0444u0430u0440u043cu0430u0446u0435u0432u0442u0438u0447u0435u0441u043au0438 acceptable filler, in which the component with a controlled release profile in vitro in u0438u0441u043au0443u0441 demonstrates u0440u0430u0441u0442u0432u043eu0440u0435u043du0438u00a0 changing environment of intestinal juicewith the release of less than about 70% u0430u0433u043eu043du0438u0441u0442u0430 u0433u0430u043cu043au0432 after 1 h, the release of at least about 20% u0430u0433u043eu043du0438u0441u0442u0430 u0433u0430u043cu043au0432 after 4 h and release at me re, about 30% of u0430u0433u043eu043du0438u0441u0442u0430 u0433u0430u043cu043au0432 after 6 hours.;2. u0444u0430u0440u043cu0430u0446u0435u0432u0442u0438u0447u0435u0441u043au0430u00a0 u043bu0435u043au0430u0440u0441u0442u0432u0435u043du043du0430u00a0 form on w.1, in which the component with a controlled release profile u0440u0430u0441u0442u0432u043eu0440u0435u043du0438u00a0 demonstrated in vitro in the artificial environment of digestive juice / artificial environment u043au0438u0448u0435u0447u043d wow juice (change of environment after 1 h), including the release of less than about 80% u0430u0433u043eu043du0438u0441u0442u0430 u0433u0430u043cu043au0432 after 1 h, the release of at least 30% u0430u0433u043eu043du0438u0441u0442u0430 u0433u0430u043cu043au0432 after 4 h, and the release of at leastabout 40% of u0430u0433u043eu043du0438u0441u0442u0430 u0433u0430u043cu043au0432 after 6 hours.;3. u0444u0430u0440u043cu0430u0446u0435u0432u0442u0438u0447u0435u0441u043au0430u00a0 u043bu0435u043au0430u0440u0441u0442u0432u0435u043du043du0430u00a0 form 1, in which the component with a controlled release profile u0440u0430u0441u0442u0432u043eu0440u0435u043du0438u00a0 demonstrates in vitro in artificial environment. u0448u0435u0447u043du043eu0433u043e juice, including release of less than about 50% u0430u0433u043eu043du0438u0441u0442u0430 u0433u0430u043cu043au0432 after 1 h, the release of at least about 40% u0430u0433u043eu043du0438u0441u0442u0430 u0433u0430u043cu043au0432 after 4 h, and release at least about 50% u0430u0433u043eu043du0438u0441u0442u0430 u0433u0430u043cu043au0432 after 6 hours.;4. u0444u0430u0440u043cu0430u0446u0435u0432u0442u0438u0447u0435u0441u043au0430u00a0 u043bu0435u043au0430u0440u0441u0442u0432u0435u043du043du0430u00a0 form on w.3, in which the component with a controlled release profile u0440u0430u0441u0442u0432u043eu0440u0435u043du0438u00a0 demonstrated in vitro in the artificial environment of digestive juice / artificial environment u043au0438u0448u0435u0447u043d wow juice (change of environment after 1 h), including the release of less than about 70% u0430u0433u043eu043du0438u0441u0442u0430 u0433u0430u043cu043au0432 after 1 h, the release of at least about 40% u0430u0433u043eu043du0438u0441u0442u0430 u0433u0430u043cu043au0432 after 4 h, and the release of at leastabout 50% of u0430u0433u043eu043du0438u0441u0442u0430 u0433u0430u043cu043au0432 after 6 hours.;5. u0444u0430u0440u043cu0430u0446u0435u0432u0442u0438u0447u0435u0441u043au0430u00a0 u043bu0435u043au0430u0440u0441u0442u0432u0435u043du043du0430u00a0 form on w.1, further u0441u043eu0434u0435u0440u0436u0430u0449u0430u00a0 with immediate release component containing the agonist u0433u0430u043cu043au0432 and u0444u0430u0440u043cu0430u0446u0435u0432u0442u0438u0447u0435u0441u043au0438 acceptable filler, which are two component with immediate release profile u0440u0430u0441u0442u0432u043eu0440u0435u043du0438u00a0 demonstrates in vitro, including the release of at leastabout 80% of u0430u0433u043eu043du0438u0441u0442u0430 u0433u0430u043cu043au0432 after 1 h in simulated gastric environment and in which the ratio of the component and the u0432u044bu0441u0432u043eu0431u043eu0436u0434u0430u044eu0449u0435u0433u043eu0441u00a0 immediately controlled u0432u044bu0441u0432u043eu0431u043eu0436u0434u0430u044eu0449u0435u0433u043eu0441u00a0 component u0441u043eu0441u0442u0430u0432u043bu00a0u0435u0442 from about 1: 10 to about 10: 1.;6. u0444u0430u0440u043cu0430u0446u0435u0432u0442u0438u0447u0435u0441u043au0430u00a0 u043bu0435u043au0430u0440u0441u0442u0432u0435u043du043du0430u00a0 form under clause 5, in which the agonist u0440u0435u0446u0435u043fu0442u043eu0440u0430 u0433u0430u043cu043au0432 u00a0u0432u043bu00a0u0435u0442u0441u00a0 u0431u0430u043au043bu043eu0444u0435u043du043eu043c.;7. u0444u0430u0440u043cu0430u0446u0435u0432u0442u0438u0447u0435u0441u043au0430u00a0 u043bu0435u043au0430u0440u0441u0442u0432u0435u043du043du0430u00a0 form for p.6, in which the ratio of the immediately u0432u044bu0441u0432u043eu0431u043eu0436u0434u0430u044eu0449u0435u0433u043eu0441u00a0 component and the controlled u0432u044bu0441u0432u043eu0431u043eu0436u0434u0430u044eu0449u0435u0433u043eu0441u00a0 u043au043eu043cu043fu043eu043d yente u0441u043eu0441u0442u0430u0432u043bu00a0u0435u0442 from about 1 to about 4: 4: 1.;8. u0444u0430u0440u043cu0430u0446u0435u0432u0442u0438u0447u0435u0441u043au0430u00a0 u043bu0435u043au0430u0440u0441u0442u0432u0435u043du043du0430u00a0 form for p.6, in which the ratio of the immediately u0432u044bu0441u0432u043eu0431u043eu0436u0434u0430u044eu0449u0435u0433u043eu0441u00a0 component and the controlled u0432u044bu0441u0432u043eu0431u043eu0436u0434u0430u044eu0449u0435u0433u043eu0441u00a0 u043au043eu043cu043fu043eu043d yente u0441u043eu0441u0442u0430u0432u043bu00a0u0435u0442 from about 1: 1 to about 2: 1.;9.u0444u0430u0440u043cu0430u0446u0435u0432u0442u0438u0447u0435u0441u043au0430u00a0 u043bu0435u043au0430u0440u0441u0442u0432u0435u043du043du0430u00a0 form, u0441u043eu0434u0435u0440u0436u0430u0449u0430u00a0 himself covered in u044du043du0442u0435u0440u043eu0441u043eu043bu044eu0431u0438u043bu044cu043du043eu0439 shell component with controlled release.where the coated u044du043du0442u0435u0440u043eu0441u043eu043bu044eu0431u0438u043bu044cu043du043eu0439 shell component with controlled release contains the agonist u0433u0430u043cu043au0432 and u0444u0430u0440u043cu0430u0446u0435u0432u0442u0438u0447u0435u0441u043au0438 acceptable u043du0430u043fu043eu043bu043d u0438u0442u0435u043bu044c and where the coated u044du043du0442u0435u0440u043eu0441u043eu043bu044eu0431u0438u043bu044cu043du043eu0439 shell component with controlled release profile u0440u0430u0441u0442u0432u043eu0440u0435u043du0438u00a0 demonstrates in vitro in a cp food gastric / intestinal juice and artificial environment (environment u043fu0440u043eu0448u0435u0441u0442the wii 2 h), including the release of less than about 10% u0430u0433u043eu043du0438u0441u0442u0430 u0433u0430u043cu043au0432 after 2 h, the release of at least about 40% u0430u0433u043eu043du0438u0441u0442u0430 u0433u0430u043cu043au0432 after 3 h, and the release of for me u043du044cu0448u0435u0439 least, about 70% of u0430u0433u043eu043du0438u0441u0442u0430 u0433u0430u043cu043au0432 after 6 hours.;10. u0444u0430u0440u043cu0430u0446u0435u0432u0442u0438u0447u0435u0441u043au0430u00a0 u043bu0435u043au0430u0440u0441u0442u0432u0435u043du043du0430u00a0 form on w.9, in which the coated u044du043du0442u0435u0440u043eu0441u043eu043bu044eu0431u0438u043bu044cu043du043eu0439 shell component with controlled release profile u0440u0430u0441u0442u0432u043eu0440u0435u043du0438u00a0 demonstrates in vitro in a cp food gastric / intestinal juice artificial environment (change of environment after 2 h), including the release of less than about 10% u0430u0433u043eu043du0438u0441u0442u0430 u0433u0430u043cu043au0432 after 2 h, u0432u044bu0441u0432u043eu0431 u043eu0436u0434u0435u043du0438u0435 at leastabout 50% of u0430u0433u043eu043du0438u0441u0442u0430 u0433u0430u043cu043au0432 after 3 h and the release of at least about 80% u0430u0433u043eu043du0438u0441u0442u0430 u0433u0430u043cu043au0432 after 6 hours.;11. u0444u0430u0440u043cu0430u0446u0435u0432u0442u0438u0447u0435u0441u043au0430u00a0 u043bu0435u043au0430u0440u0441u0442u0432u0435u043du043du0430u00a0 form on w.10, in which the coated u044du043du0442u0435u0440u043eu0441u043eu043bu044eu0431u0438u043bu044cu043du043eu0439 shell component with controlled release profile u0440u0430u0441u0442u0432u043eu0440u0435u043du0438u00a0 demonstrates in vitro in artificial in red gastric / intestinal juice artificial environment (change of environment after 2 h), including the release of less than about 10% u0430u0433u043eu043du0438u0441u0442u0430 u0433u0430u043cu043au0432 after 2 h, u0432u044bu0441u0432u043e u0431u043eu0436u0434u0435u043du0438u0435 at leastabout 60% of u0430u0433u043eu043du0438u0441u0442u0430 u0433u0430u043cu043au0432 after 3 h and the release of at least about 90% u0430u0433u043eu043du0438u0441u0442u0430 u0433u0430u043cu043au0432 after 6 hours.;12. u0444u0430u0440u043cu0430u0446u0435u0432u0442u0438u0447u0435u0441u043au0430u00a0 u043bu0435u043au0430u0440u0441u0442u0432u0435u043du043du0430u00a0 form on w.9, further u0441u043eu0434u0435u0440u0436u0430u0449u0430u00a0 with immediate release component containing the agonist u0433u0430u043cu043au0432 and u0444u0430u0440u043cu0430u0446u0435u0432u0442u0438u0447u0435u0441u043au0438 acceptable filler, which are two component with immediate release profile u0440u0430u0441u0442u0432u043eu0440u0435u043du0438u00a0 demonstrates in vitro, including the release of at leastabout 80% of u0430u0433u043eu043du0438u0441u0442u0430 u0433u0430u043cu043au0432 after 1 h in the artificial environment of digestive juice; and in which the ratio of the component and the u0432u044bu0441u0432u043eu0431u043eu0436u0434u0430u044eu0449u0435u0433u043eu0441u00a0 immediately controlled u0432u044bu0441u0432u043eu0431u043eu0436u0434u0430u044eu0449u0435u0433u043eu0441u00a0 component u0441u043eu0441u0442u0430u0432u043bu00a0u0435u0442 from about 1: 10 to about 10: 1.;13. u0444u0430u0440u043cu0430u0446u0435u0432u0442u0438u0447u0435u0441u043au0430u00a0 u043bu0435u043au0430u0440u0441u0442u0432u0435u043du043du0430u00a0 form on p.12, in which the agonist u0433u0430u043cu043au0432 u00a0u0432u043bu00a0u0435u0442u0441u00a0 u0431u0430u043au043bu043eu0444u0435u043du043eu043c.;14. u0444u0430u0440u043cu0430u0446u0435u0432u0442u0438u0447u0435u0441u043au0430u00a0 u043bu0435u043au0430u0440u0441u0442u0432u0435u043du043du0430u00a0 form on p.13, in which the ratio of the immediately u0432u044bu0441u0432u043eu0431u043eu0436u0434u0430u044eu0449u0435u0433u043eu0441u00a0 component and the controlled u0432u044bu0441u0432u043eu0431u043eu0436u0434u0430u044eu0449u0435u0433u043eu0441u00a0 u043au043eu043cu043fu043eu043d yente u0441u043eu0441u0442u0430u0432u043bu00a0u0435u0442 from about 1 to about 4: 4: 1.;15. u0444u0430u0440u043cu0430u0446u0435u0432u0442u0438u0447u0435u0441u043au0430u00a0 u043bu0435u043au0430u0440u0441u0442u0432u0435u043du043du0430u00a0 form on p.14, in which the ratio of the immediately u0432u044bu0441u0432u043eu0431u043eu0436u0434u0430u044eu0449u0435u0433u043eu0441u00a0 component and the controlled u0432u044bu0441u0432u043eu0431u043eu0436u0434u0430u044eu0449u0435u0433u043eu0441u00a0 u043au043eu043cu043fu043eu043d yente u0441u043eu0441u0442u0430u0432u043bu00a0u0435u0442 from about 1: 1 to about 2: 1.;16.u0444u0430u0440u043cu0430u0446u0435u0432u0442u0438u0447u0435u0441u043au0430u00a0 u043bu0435u043au0430u0440u0441u0442u0432u0435u043du043du0430u00a0 form, u0441u043eu0434u0435u0440u0436u0430u0449u0430u00a0 in agonist u0433u0430u043cu043au0432 and u0444u0430u0440u043cu0430u0446u0435u0432u0442u0438u0447u0435u0441u043au0438 acceptable filler, where u0443u043au0430u0437u0430u043du043du0430u00a0 u0444u0430u0440u043cu0430u0446u0435u0432u0442u0438u0447u0435u0441u043au0430u00a0 u043bu0435u043au0430u0440u0441u0442u0432u0435u043du043du0430u00a0 s u043eu0440u043cu0430 profile u0440u0430u0441u0442u0432u043eu0440u0435u043du0438u00a0 demonstrated in vitro in the artificial environment of digestive juice / artificial environment intestinal juice (change of environment after 2 h), including the release of less than about 75% u0430u0433u043eu043du0438u0441u0442u0430 u0433u0430u043cu043au0432 after 2 h and releaseat least about 80% u0430u0433u043eu043du0438u0441u0442u0430 u0433u0430u043cu043au0432 after 3 hours.;17. u0444u0430u0440u043cu0430u0446u0435u0432u0442u0438u0447u0435u0441u043au0430u00a0 u043bu0435u043au0430u0440u0441u0442u0432u0435u043du043du0430u00a0 form on p.16, where u0443u043au0430u0437u0430u043du043du0430u00a0 u0444u0430u0440u043cu0430u0446u0435u0432u0442u0438u0447u0435u0441u043au0430u00a0 u043bu0435u043au0430u0440u0441u0442u0432u0435u043du043du0430u00a0 form shows the profile u0440u0430u0441u0442u0432u043eu0440u0435u043du0438u00a0 in vitro in artificial environment. u043bu0443u0434u043eu0447u043du043eu0433u043e juice / artificial environment intestinal juice (change of environment after 2 h), including the release of less than about 65% after 2 h and u0432u044bu0441u0432u043eu0431u043eu0436u0434u0435 u0430u0433u043eu043du0438u0441u0442u0430 u0433u0430u043cu043au0432 we, at least, about 90% of u0430u0433u043eu043du0438u0441u0442u0430 u0433u0430u043cu043au0432 after 3 hours.;18. u0444u0430u0440u043cu0430u0446u0435u0432u0442u0438u0447u0435u0441u043au0430u00a0 u043bu0435u043au0430u0440u0441u0442u0432u0435u043du043du0430u00a0 form on p.16, in which the agonist u0433u0430u043cu043au0432 u00a0u0432u043bu00a0u0435u0442u0441u00a0 u0431u0430u043au043bu043eu0444u0435u043du043eu043c;19. u0444u0430u0440u043cu0430u0446u0435u0432u0442u0438u0447u0435u0441u043au0430u00a0 u043bu0435u043au0430u0440u0441u0442u0432u0435u043du043du0430u00a0 form, u0441u043eu0434u0435u0440u0436u0430u0449u0430u00a0 baclofen and u0444u0430u0440u043cu0430u0446u0435u0432u0442u0438u0447u0435u0441u043au0438 acceptable filler, where the oral introduction of the pharmaceutical le u043au0430u0440u0441u0442u0432u0435u043du043du043eu0439 form the average time period for which in vivo, subject to receiving your u0430u0431u0441u043eu0440u0431u0438u0440u0443u0435u0442u0441u00a0, at least 80% of the u0431u0430u043au043bu043eu0444u0435u043du0430, u0441u043eu0441u0442u0430u0432u043bu00a0u0435u0442 ball its 2.5 hours.;20. u0444u0430u0440u043cu0430u0446u0435u0432u0442u0438u0447u0435u0441u043au0430u00a0 u043bu0435u043au0430u0440u0441u0442u0432u0435u043du043du0430u00a0 form on p.19, where by the oral intake of the pharmaceutical drug forms for which the average time period in vivo, subject to receiving your u0430u0431u0441u043eu0440u0431u0438u0440u0443u0435u0442u0441u00a0, at least 80% of the u0431u0430u043au043bu043eu0444u0435u043du0430, u0441u043eu0441u0442u0430u0432u043bu00a0u0435u0442 from about 3 to about 4.5 hours.;21. u0444u0430u0440u043cu0430u0446u0435u0432u0442u0438u0447u0435u0441u043au0430u00a0 u043bu0435u043au0430u0440u0441u0442u0432u0435u043du043du0430u00a0 form on p.20, u0432u043au043bu044eu0447u0430u044eu0449u0430u00a0 coated controlled release u044du043du0442u0435u0440u043eu0441u043eu043bu044eu0431u0438u043bu044cu043du043eu0439 shell component and the component with the u043du0435u043cu0435u0434u043bu0435u043du043d ies release.;22. u0444u0430u0440u043cu0430u0446u0435u0432u0442u0438u0447u0435u0441u043au0430u00a0 u043bu0435u043au0430u0440u0441u0442u0432u0435u043du043du0430u00a0 form on w.21, in which the coated controlled release u044du043du0442u0435u0440u043eu0441u043eu043bu044eu0431u0438u043bu044cu043du043eu0439 shell component contains a polymer selected from the group u0441u043eu0441u0442u043eu00a0u0449u0435u0439 of u0444u0442u0430u043bu0430u0442u0430 cellulose acetate cellulose acetate, u0442u0440u0438u043cu0435u043bu043bu0438u0442u0430u0442u0430, u0444u0442u0430u043bu0430u0442u0430 u0433u0438u0434u0440u043eu043au0441u0438u043fu0440u043eu043fu0438u043bu043cu0435u0442u0438u043bu0446u0435u043bu043bu044eu043bu043eu0437u044b, u0444u0442u0430u043bu0430u0442u0430 u043fu043eu043bu0438u0432u0438u043du0438u043bu0430u0446u0435u0442u0430u0442u0430, u043au0430u0440u0431u043eu043au0441u0438u043cu0435u0442u0438u043bu044du0442u0438u043bu0446u0435u043bu043bu044eu043bu043eu0437u044b, u0441u043eu043fu043eu043bu0438 u043cu0435u0440u0438u0437u043eu0432u0430u043du043du043eu0439 u043cu0435u0442u0430u043au0440u0438u043bu043eu0432u043eu0439 acidu043cu0435u0442u0438u043bu043eu0432u044bu0445 ethers u043cu0435u0442u0430u043au0440u0438u043bu043eu0432u043eu0439 acid and their mixtures.;23. u0444u0430u0440u043cu0430u0446u0435u0432u0442u0438u0447u0435u0441u043au0430u00a0 u043bu0435u043au0430u0440u0441u0442u0432u0435u043du043du0430u00a0 form p.21, provided the drug form for oral u0432u0432u0435u0434u0435u043du0438u00a0 before u0443u043au0430u0437u0430u043du043du0430u00a0 u043bu0435u043au0430u0440u0441u0442u0432u0435u043du043du0430u00a0 form security the profile u0441u043eu0434u0435u0440u0436u0430u043du0438u00a0 in blood plasma in vivo, including average maximum u0443u0440u043eu0432u043du00a0 u0431u0430u043au043bu043eu0444u0435u043du0430 from about 2.5 hours to about 5.5 h after admission.;24. u0444u0430u0440u043cu0430u0446u0435u0432u0442u0438u0447u0435u0441u043au0430u00a0 u043bu0435u043au0430u0440u0441u0442u0432u0435u043du043du0430u00a0 form p.21, where u0443u043au0430u0437u0430u043du043du0430u00a0 u043bu0435u043au0430u0440u0441u0442u0432u0435u043du043du0430u00a0 form provides a profile u0441u043eu0434u0435u0440u0436u0430u043du0438u00a0 in blood plasma in vivo in a stationary u0441u043eu0441u0442u043eu00a0u043du0438u0438 included expecting consolations Cmin approximately 12 h after u0432u0432u0435u0434u0435u043du0438u00a0 the drug form.;25. u0444u0430u0440u043cu0430u0446u0435u0432u0442u0438u0447u0435u0441u043au0430u00a0 u043bu0435u043au0430u0440u0441u0442u0432u0435u043du043du0430u00a0 form on any of the u043fu043f.6, 13, 18, or 19, in which the baclofen u0441u043eu0434u0435u0440u0436u0438u0442u0441u00a0 ranging in number from about 2 mg to about 150 mg.;26. u0444u0430u0440u043cu0430u0446u0435u0432u0442u0438u0447u0435u0441u043au0430u00a0 u043bu0435u043au0430u0440u0441u0442u0432u0435u043du043du0430u00a0 form on p.25, in which the baclofen u0441u043eu0434u0435u0440u0436u0438u0442u0441u00a0 of about 20 mg.;27. u0444u0430u0440u043cu0430u0446u0435u0432u0442u0438u0447u0435u0441u043au0430u00a0 u043bu0435u043au0430u0440u0441u0442u0432u0435u043du043du0430u00a0 form on p.25, in which the baclofen u0441u043eu0434u0435u0440u0436u0438u0442u0441u00a0 of about 25 mg.;28. u0444u0430u0440u043cu0430u0446u0435u0432u0442u0438u0447u0435u0441u043au0430u00a0 u043bu0435u043au0430u0440u0441u0442u0432u0435u043du043du0430u00a0 form on p.25, in which the baclofen u0441u043eu0434u0435u0440u0436u0438u0442u0441u00a0 of about 30 mg.;29. u0444u0430u0440u043cu0430u0446u0435u0432u0442u0438u0447u0435u0441u043au0430u00a0 u043bu0435u043au0430u0440u0441u0442u0432u0435u043du043du0430u00a0 form on p.25, in which the baclofen u0441u043eu0434u0435u0440u0436u0438u0442u0441u00a0 of about 35 mg.;30. u0444u0430u0440u043cu0430u0446u0435u0432u0442u0438u0447u0435u0441u043au0430u00a0 u043bu0435u043au0430u0440u0441u0442u0432u0435u043du043du0430u00a0 form on p.25, in which the baclofen u0441u043eu0434u0435u0440u0436u0438u0442u0441u00a0 of about 40 mg.;31. u0444u0430u0440u043cu0430u0446u0435u0432u0442u0438u0447u0435u0441u043au0430u00a0 u043bu0435u043au0430u0440u0441u0442u0432u0435u043du043du0430u00a0 form on any of the u043fu043f.6, 13, 18, or 19, in which the baclofen is as u043au043eu043cu0431u0438u043du0430u0446u0438u00a0 granules with immediate release and gr u0430u043du0443u043b with controlled release.;32. u0444u0430u0440u043cu0430u0446u0435u0432u0442u0438u0447u0435u0441u043au0430u00a0 u043bu0435u043au0430u0440u0441u0442u0432u0435u043du043du0430u00a0 form p.31, where u0443u043au0430u0437u0430u043du043du0430u00a0 u043bu0435u043au0430u0440u0441u0442u0432u0435u043du043du0430u00a0 form u00a0u0432u043bu00a0u0435u0442u0441u00a0 tab.;33. u0444u0430u0440u043cu0430u0446u0435u0432u0442u0438u0447u0435u0441u043au0430u00a0 u043bu0435u043au0430u0440u0441u0442u0432u0435u043du043du0430u00a0 form p.31, where u0443u043au0430u0437u0430u043du043du0430u00a0 u043bu0435u043au0430u0440u0441u0442u0432u0435u043du043du0430u00a0 form u00a0u0432u043bu00a0u0435u0442u0441u00a0 capsule.;34.u0444u0430u0440u043cu0430u0446u0435u0432u0442u0438u0447u0435u0441u043au0430u00a0 u043bu0435u043au0430u0440u0441u0442u0432u0435u043du043du0430u00a0 form, u0441u043eu0434u0435u0440u0436u0430u0449u0430u00a0 baclofen in the immediately u0432u044bu0441u0432u043eu0431u043eu0436u0434u0430u044eu0449u0435u0433u043eu0441u00a0 component and of the u044du043du0442u0435u0440u043eu0441u043eu043bu044eu0431u0438u043bu044cu043du043eu0439 shell with a controlled release component, in which the coated u044du043du0442u0435u0440u043eu0441u043eu043bu044eu0431u0438u043bu044cu043du043eu0439 shell component with controlled release contains u043fu043eu043bu0438u043c ep, selected from the group u0441u043eu0441u0442u043eu00a0u0449u0435u0439 of u0444u0442u0430u043bu0430u0442u0430 acetate celluloseu0442u0440u0438u043cu0435u043bu043bu0438u0442u0430u0442u0430 acetate cellulose u0444u0442u0430u043bu0430u0442u0430 u0433u0438u0434u0440u043eu043au0441u0438u043fu0440u043eu043fu0438u043bu043cu0435u0442u0438u043bu0446u0435u043bu043bu044eu043bu043eu0437u044b, u0444u0442u0430u043bu0430u0442u0430 u043fu043eu043bu0438u0432u0438u043du0438u043bu0430u0446u0435u0442u0430u0442u0430, u043au0430u0440u0431u043eu043au0441u0438u043cu0435u0442u0438u043bu044du0442u0438u043bu0446u0435u043bu043bu044eu043bu043eu0437u044b, u0441u043eu043fu043eu043bu0438u043cu0435u0440u0438u0437u043eu0432u0430u043du043du043eu0439 u043cu0435u0442u0430u043au0440u0438u043bu043eu0432u043eu0439 acid, u043cu0435u0442u0438u043bu043eu0432u044bu0445 ethers u043cu0435u0442u0430u043au0440u0438u043bu043eu0432u043eu0439 acid and their mixtures, and is provided u0432u0432u0435u0434u0435u043du0438u00a0 oral drug form the average lag time, z and that in vivo in u0443u0441u043bu043eu0432u0438u00a0u0445 admission on an empty stomach u0430u0431u0441u043eu0440u0431u0438u0440u0443u0435u0442u0441u00a0 at least80% of the u0431u0430u043au043bu043eu0444u0435u043du0430, u0441u043eu0441u0442u0430u0432u043bu00a0u0435u0442 from about 3 to about 4.5 hours.;35. u0444u0430u0440u043cu0430u0446u0435u0432u0442u0438u0447u0435u0441u043au0430u00a0 u043bu0435u043au0430u0440u0441u0442u0432u0435u043du043du0430u00a0 form p.34, where the polymer u00a0u0432u043bu00a0u0435u0442u0441u00a0 u0441u043eu043fu043eu043bu0438u043cu0435u0440u0438u0437u043eu0432u0430u043du043du043eu0439 u043cu0435u0442u0430u043au0440u0438u043bu043eu0432u043eu0439 acid.;36.u0444u0430u0440u043cu0430u0446u0435u0432u0442u0438u0447u0435u0441u043au0430u00a0 u043bu0435u043au0430u0440u0441u0442u0432u0435u043du043du0430u00a0 form, u0441u043eu0434u0435u0440u0436u0430u0449u0430u00a0 baclofen in the immediately u0432u044bu0441u0432u043eu0431u043eu0436u0434u0430u044eu0449u0435u0433u043eu0441u00a0 component and of the u044du043du0442u0435u0440u043eu0441u043eu043bu044eu0431u0438u043bu044cu043du043eu0439 shell components with controlled release.in which the coated controlled release u044du043du0442u0435u0440u043eu0441u043eu043bu044eu0431u0438u043bu044cu043du043eu0439 shell component includes u0441u0435u0431u00a0 u043cu0430u0442u0440u0438u043au0441u043du0443u044e medicinal form; and where the ca u043bu043eu0432u0438u0438 oral intake and the drug form, the average time period for which in vivo, subject to receiving your u0430u0431u0441u043eu0440u0431u0438u0440u0443u0435u0442u0441u00a0, at least 80% of the u0431u0430u043au043bu043eu0444u0435u043du0430, u0441u043eu0441u0442u0430u0432u043bu00a0u0435u0442 from about 3 to about 4.5 hours.
展开▼